<DOC>
	<DOCNO>NCT01576419</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety PG201 osteoarthritis patient . This clinical study designate non-inferiority test level significance : 95 % , α=0.05 . Type 2 error ( β ) set 0.2 , power test set 80 % . Assuming 20 % drop-out rate , number subject require treatment group estimate 154 , total number subject require study 308. non-inferiority margin : 8mm</brief_summary>
	<brief_title>Active Drug Comparative , Multi-center , phase3 Clinical Study Evaluate Efficacy Safety PG201 Osteoarthritis Patients</brief_title>
	<detailed_description>Patients PG201 group prescribe two PG201 tablet per day ( BID ) one celecoxib placebo capsule morning even per day 8 week . Patients celecoxib group prescribe celecoxib 200 mg ( one 200 mg capsule one celecoxib placebo capsule ) one PG201 placebo tablet morning even per day 8 week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Patients ≥40 ≤ 80years age . 2 . Patients meet American College Rheumatology clinical plus radiographic classification criterion idiopathic osteoarthritis knee , define follow : patient knee pain radiographically diagnose osteophyte meet least one following . Age &gt; 50 year . Morning stiffness le 30 minute . Crepitus movement weightbearing knee . 3 . Patients symptomatic primary osteoarthritis knee least last 3 month prior screen . 4 . Patients receive Nonsteroidal antiinflammatory drug ( NSAIDs ) /Cyclooxygenase2 inhibitor treatment arthritis knee least 5 day week 4 week prior screen . 5 . Patients score 100mm pain VAS ≤80 mm screening . 6 . Patients score 100mm pain VAS ≥50 mm baseline . 7 . Patients able willing provide write informed consent . 1 . Patients history surgery arthroscopy study joint within previous 6 month . 2 . Patients trauma study joint within previous 12 month . 3 . Patients symptomatic hip osteoarthritis , condition would interfere study assessment . 4 . Patients type arthritis , active malignancy active GI , cardiovascular , renal , hepatic , neurologic , psychiatric disease . 5 . Patients know hypersensitivity intolerance Nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin Cyclooxygenase2 inhibitor . 6 . Patients uncontrollable hypertension . 7 . Patients creatinine , bilirubin , Alanine aminotransferase Aspartate aminotransferase &gt; 1.5 time Upper Lange normal screening . 8 . Patients history drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>PG201</keyword>
	<keyword>Non-inferiority</keyword>
	<keyword>100mm pain VAS</keyword>
</DOC>